ADMA Biologics Inc. (NASDAQ: ADMA) responded to a report published by Culper Research on March 24 that contained negative assertions about the company. The biopharmaceutical company stated the report contains "misleading, false and inaccurate statements" and is based on "speculative assertions derived from unidentified and unreliable sources."

Culper Research disclosed it holds a short position in ADMA stock. The research firm has previously published similar reports on other public companies after taking short positions.

ADMA said it takes seriously its obligations to report operating and financial results accurately and make public disclosures in accordance with Securities and Exchange Commission rules and U.S. Generally Accepted Accounting Principles standards. The company stated it is reviewing the assertions made in the report.

ADMA operates as a commercial biopharmaceutical company that manufactures and markets plasma-derived biologics. The company currently sells three FDA-approved products: ASCENIV for primary humoral immunodeficiency treatment, BIVIGAM for the same condition, and NABI-HB for hepatitis B immunity enhancement.

The company operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida, and collects source plasma through its ADMA BioCenters subsidiary. ADMA is also developing SG-001, a pre-clinical investigative treatment targeting S. pneumonia.